Westpac is challenging a judge’s order that gives the funder backing a class action over life insurance premiums a 25 percent cut of any recovery.
Three class actions filed against the Commonwealth of Australia over allegedly toxic foam from government military bases will be heard together.
Law firm Quinn Emanuel Urquhart & Sullivan will call in US experts to back up its proposed “step up” funding model as five law firms begin a high stakes battle to lead a shareholder class action against AMP.
Shine Lawyers has acquired boutique class action firm ACA lawyers, a deal that will create the second largest class action firm in Australia by caseload and position the firm to take advantage of an expected increase in shareholder class action work.
The funder underwriting a class action against Westpac will take a 25 percent cut of the net — not gross — recovery sum to secure a judge’s approval of a common fund order in the case.
A landmark ruling that transferred four competing federal class actions against AMP to state court will stand, with the law firms behind the cases opting out of a fight in the High Court.
A judge has agreed to sign off on an order in a massive class action against Westpac that could give 25 percent of any recovery to the litigation funder underwriting the case, on the condition that the funder accept a rate reflecting the net, not the gross, sum.
AMP has prevailed in a hard-fought fight over where it will defend five shareholder class actions brought in the wake of the Banking Royal Commission, in a precedent-setting judgement that provides a road map for future jurisdictional battles over competing class actions.
The Full Federal Court has handed Johnson & Johnson unit Ethicon a victory in the class action over its allegedly defective vaginal mesh devices, partly reversing a judge’s decision that expanded the class post-trial.
Lawyers on both sides of the class action against American Medical Services over pelvic mesh implants have taken steps to ensure the case proceeds with greater efficiency than the pelvic mesh class action against Johnson & Johnson, which went to an 89-day trial five years after that case was filed.